Benzinga | Nov 8, 2021 07:33AM EST

Galmed Pharmaceuticals Q3 EPS $(0.31) Beats $(0.36) Estimate

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.36) by 13.89 percent. This is a 3.13 percent increase over losses of $(0.32) per share from the same period last year.